Recent News

• 03.07.2025 - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 03.07.2025 - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 02.25.2025 - ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones
• 02.25.2025 - ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones
• 02.18.2025 - ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
• 02.18.2025 - ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
• 02.11.2025 - Oppenheimer 35th Annual Healthcare Life Sciences Conference
• 02.11.2025 - Oppenheimer 35th Annual Healthcare Life Sciences Conference
• 02.07.2025 - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 02.07.2025 - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2025 - 8-K Current report
• 02.25.2025 - EX-99.1 EX-99.1
• 02.18.2025 - 8-K Current report
• 02.18.2025 - EX-99.1 EX-99.1
• 02.18.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors